
First approved for adults in 2022, the therapy is now cleared for children 12-18 with symptomatic obstructive hypertrophic cardiomyopathy.
Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.
Don’t get left behind: Sign up today for our






